DK1136475T3 - Piperidin- og piperazinderivater til anvendelse i behandlingen af Alzheimer - Google Patents
Piperidin- og piperazinderivater til anvendelse i behandlingen af AlzheimerInfo
- Publication number
- DK1136475T3 DK1136475T3 DK01105498T DK01105498T DK1136475T3 DK 1136475 T3 DK1136475 T3 DK 1136475T3 DK 01105498 T DK01105498 T DK 01105498T DK 01105498 T DK01105498 T DK 01105498T DK 1136475 T3 DK1136475 T3 DK 1136475T3
- Authority
- DK
- Denmark
- Prior art keywords
- halogen
- alkyl
- hydrogen
- compounds
- independently
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 150000004885 piperazines Chemical class 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000006870 function Effects 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000007996 neuronal plasticity Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/02—Preparation by ring-closure or hydrogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00106210 | 2000-03-22 | ||
| EP01105498A EP1136475B1 (en) | 2000-03-22 | 2001-03-15 | Piperidine and piperazine compounds for use in the treatment of Alzheimer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1136475T3 true DK1136475T3 (da) | 2004-12-27 |
Family
ID=8168189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01105498T DK1136475T3 (da) | 2000-03-22 | 2001-03-15 | Piperidin- og piperazinderivater til anvendelse i behandlingen af Alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6605723B2 (da) |
| EP (1) | EP1136475B1 (da) |
| JP (1) | JP3598277B2 (da) |
| KR (1) | KR100378331B1 (da) |
| CN (1) | CN1218941C (da) |
| AT (1) | ATE273953T1 (da) |
| CA (1) | CA2341010C (da) |
| DE (1) | DE60104923T2 (da) |
| DK (1) | DK1136475T3 (da) |
| ES (1) | ES2225330T3 (da) |
| JO (1) | JO2275B1 (da) |
| MX (1) | MXPA01002945A (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204129D0 (en) * | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
| US7569691B2 (en) * | 2005-04-20 | 2009-08-04 | Shin-Etsu Chemical Co., Ltd. | Protected piperazino group-bearing organoxysilane compound and making method |
| WO2009031526A1 (ja) | 2007-09-06 | 2009-03-12 | National University Corporation Hokkaido University | 光学活性３－キヌクリジノール誘導体の製造方法 |
| JP5276093B2 (ja) * | 2008-04-07 | 2013-08-28 | 日本曹達株式会社 | 光学活性アミノアルコール化合物の製造方法 |
| CN102126995A (zh) * | 2010-12-14 | 2011-07-20 | 台州市华南医化有限公司 | 一种改进的苯基乙烯基砜的制备工艺 |
| CN102617451B (zh) * | 2012-02-22 | 2014-01-22 | 华东理工大学 | 具有杀虫活性的哌啶醇衍生物、及其制备和用途 |
| CN110240561B (zh) * | 2018-03-07 | 2020-08-04 | 新发药业有限公司 | 一种低成本的3-羟基吡啶的制备方法 |
| CN110734393B (zh) * | 2019-11-11 | 2022-02-25 | 南京恒远科技开发有限公司 | N-苄基-3-氧代哌啶-4-羧酸乙酯盐酸盐的制备方法 |
| CN119039289A (zh) * | 2024-07-30 | 2024-11-29 | 安庆多辉生物科技有限公司 | 一种阿达格西布合成用新型中间体及制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4410822A1 (de) | 1994-03-24 | 1995-09-28 | Schering Ag | Neue Piperidin-Derivate |
| CA2164685C (en) | 1994-12-07 | 2005-03-08 | Takeshi Ohkuma | Method for producing an alcohol |
| JP4144814B2 (ja) | 1997-09-05 | 2008-09-03 | 長谷川香料株式会社 | 光学活性アルコール化合物の製造方法 |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
-
2001
- 2001-03-15 ES ES01105498T patent/ES2225330T3/es not_active Expired - Lifetime
- 2001-03-15 DE DE60104923T patent/DE60104923T2/de not_active Expired - Lifetime
- 2001-03-15 AT AT01105498T patent/ATE273953T1/de active
- 2001-03-15 EP EP01105498A patent/EP1136475B1/en not_active Expired - Lifetime
- 2001-03-15 DK DK01105498T patent/DK1136475T3/da active
- 2001-03-15 US US09/809,691 patent/US6605723B2/en not_active Expired - Fee Related
- 2001-03-19 CA CA002341010A patent/CA2341010C/en not_active Expired - Fee Related
- 2001-03-19 JO JO200133A patent/JO2275B1/en active
- 2001-03-20 MX MXPA01002945A patent/MXPA01002945A/es unknown
- 2001-03-20 KR KR10-2001-0014265A patent/KR100378331B1/ko not_active Expired - Fee Related
- 2001-03-22 JP JP2001082991A patent/JP3598277B2/ja not_active Expired - Fee Related
- 2001-03-22 CN CNB011118776A patent/CN1218941C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP3598277B2 (ja) | 2004-12-08 |
| CN1218941C (zh) | 2005-09-14 |
| JP2001270865A (ja) | 2001-10-02 |
| DE60104923D1 (de) | 2004-09-23 |
| CA2341010A1 (en) | 2001-09-22 |
| KR100378331B1 (ko) | 2003-05-09 |
| EP1136475B1 (en) | 2004-08-18 |
| CN1315319A (zh) | 2001-10-03 |
| MXPA01002945A (es) | 2002-08-06 |
| DE60104923T2 (de) | 2005-08-25 |
| US6605723B2 (en) | 2003-08-12 |
| CA2341010C (en) | 2009-09-08 |
| ATE273953T1 (de) | 2004-09-15 |
| JO2275B1 (en) | 2005-04-07 |
| KR20010100822A (ko) | 2001-11-14 |
| ES2225330T3 (es) | 2005-03-16 |
| US20010037026A1 (en) | 2001-11-01 |
| EP1136475A1 (en) | 2001-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PY0106469A (es) | Nuevos derivados de piperazina | |
| BR0007424A (pt) | Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto | |
| SG128491A1 (en) | Heterocyclic sulfonamide inhibitors of beta amyloid production | |
| ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| MX9705385A (es) | Derivados de n-(4-aril-tiazol-2-il)-sulfonamida. | |
| DK1136475T3 (da) | Piperidin- og piperazinderivater til anvendelse i behandlingen af Alzheimer | |
| BR0115609A (pt) | Agentes serotonérgicos | |
| ATE251139T1 (de) | (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten | |
| NO20000957L (no) | Forgrenede alkoksy-substituerte 2-aminopyridiner som NOS inhibitorer | |
| BR0210912A (pt) | Compostos e composições como inibidores de catepsina | |
| NO20052730L (no) | Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser | |
| DK0733051T3 (da) | Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister | |
| ES2157463T3 (es) | Derivados de pirimidina. | |
| NO20005031L (no) | Kinolin-4-yl-derivater II | |
| WO2001010860A3 (en) | Quinazolinone and azaquinazolinone derivatives | |
| DK557189D0 (da) | 1,2,3,4-tetrahydro-1,9-acridindiaminer, deres fremstilling og anvendelse som laegemidler | |
| DK0614888T3 (da) | Tetrahydrocyclopentab indol-methanaminer og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler. | |
| SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
| DK1255734T3 (da) | Hidtil ukendte isatin-derivater | |
| NO983285L (no) | Pyrido-1,2,4-tiadiazin- og pyrido-1,4-tiazinderivater, deres fremstilling og anvendelse | |
| EE200200385A (et) | Alfa-(2,4-disulfofenüül)-N-tert-butüülnitrooni jaselle farmatseutiliselt vastuvõetavate soolade uus valmistamise meetod | |
| DK592589D0 (da) | Kondenserede heterocycliske derivater af 1,2,3,4-tetrahydroacridin, deres fremstilling og anvendelse | |
| NO20012538L (no) | Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet | |
| MX9709393A (es) | Uso de derivados de fenoxipiridina para el tratamiento de enfermedades causadas por transtornos del sistema dopamina. | |
| NO20025031L (no) | Benzoksazin- og benzotiazinderivater og deres anvendelse i farmasöytiske midler |